Clinical Trial Update: Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia

View source ↗

Summary

Gemtuzumab ozogamicin has been approved for marketing for relapsed or refractory acute myeloid leukemia and acute promyelocytic leukemia based on the clinical t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Promyelocytic Leukemia

Drugs mentioned

• Gemtuzumab ozogamicin (gemtuzumab ozogamicin)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Status: APPROVED_FOR_MARKETING